支气管哮喘的发病机制及药物治疗研究进展  

Research advance on pathogenesis and drug treatment of bronchial asthma

作　　者：蒋宝安 屈斌[2] 郑辉[2] 王志亮[2] 焦波[1] 

机构地区：[1]山东大学药学院新药药理研究所,济南250012 [2]枣庄科技职业学院医学技术系基础医学教研室,山东枣庄277599

出　　处：《中国当代医药》2015年第13期35-37,41,共4页China Modern Medicine

摘　　要：支气管哮喘是一种慢性炎症引起的以气道高反应性和可逆性阻塞为特点的疾病。近年来随着对其发病机制的深入研究,尤其是对气道慢性炎症机制的全面了解,哮喘的治疗已取得很大进展。目前药物治疗是防治哮喘最有效的方法,应用广泛的药物有糖皮质激素、β2肾上腺素受体激动剂、茶碱类、M胆碱受体阻断药、过敏介质阻释药和抗白三烯药等。新型抗哮喘药物具有疗效好、不良反应少等特点,已成为研究的热点。Bronchial asthma is a disease caused by chronic inflammation and characterized by airway hyperresponsive-ness and reversible obstructive.In recent years,asthma treatment has made great progress with in-depth study of its pathogenesis,especially a comprehensive understanding of the chronic airway inflammation.Drug treatment is the most effective method of prevention and treatment of asthma,the drug widely use including corticosteroids,β2 adrenergic re-ceptor agonists,theophylline,M cholinergic receptor blocker,allergic drug release medium resistance and anti leukotriene drugs etc.A novel anti asthma drugs with the characteristics of good efficacy and less adverse reaction,has become a re-search hotspot.

关 键 词：哮喘 发病机制 药物疗法 综述 

分 类 号：R562.25[医药卫生—呼吸系统]